Naldini, Luigi,Escobar, Giulia,Gentner, Bernhard Rudolf,Mucci, Adele
申请号：
AU2018253959
公开号：
AU2018253959A1
申请日:
2018.04.20
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
A hematopoietic stem cell (HSC), a hematopoietic progenitor cell (HPC) a myeloid/monocyte-committed progenitor cell, a macrophage or a monocyte comprising a vector wherein the vector comprises at least one mir-130a and/or mir-126 target sequence operably linked to a nucleotide sequence encoding interferon-alpha (IFNa) for use in treating or preventing a cancer in a patient, wherein the HSC, the HPC, the myeloid/monocyte-committed progenitor cell, the macrophage or the monocyte is used in combination with an immune checkpoint inhibitor and/or a tumor associated antigen (TAA)-specific T-cell.
